Purpose: To assess the efficacy of interferon alpha-2b (IFNα2b) in the management of ocular surface squamous neoplasia (OSSN).
Methods: This is a retrospective, nonrandomized interventional case series study of 80 patients with 81 tumors treated with IFNα2b eye drops and/or injection combined with surgical excision when necessary. The main outcome measure was complete response or partial response based on the American Joint Committee on Cancer classification.
Results: The OSSN was classified as Tis (n = 10, 12%), T1 (n = 13, 16%), T2 (n = 6, 7%), T3 (n = 51, 63%), and T4 (n = 1, 1%). IFNα2b was used as immunotherapy alone (n = 22, 27%) or combined with surgery (n = 59, 73%). Overall (n = 81), complete response was achieved in 90% Tis, in 100% T1, in 100% T2, in 94% T3, and in 100% T4. Specifically for immunotherapy (n = 22), IFNα2b alone achieved complete response in 75% (3/4) Tis, in 100% (8/8) T1, and in 70% (7/10) T3. Planned IFNα2b plus surgery (n = 59) achieved control in 100% (6/6) Tis, in 100% (5/5) T1, in 100% (6/6) T2, in 100% (41/41) T3, and in 100% (1/1) T4. Tumor recurrence was noted in 5% (4/81) of cases over a median follow-up of 1 year. Ocular side effects included conjunctival hyperemia (n = 4, 5%), ocular irritation (n = 3, 4%), superficial punctate keratitis (n = 3, 4%), and conjunctival follicles (n = 1, 1%). Systemic side effects included postinjection flu-like syndrome for 1 day (n = 7, 9%).
Conclusions: IFNα2b, when appropriately combined with surgical excision for OSSN, provides complete control in 95% of cases overall, specifically in 90% Tis, in 100% T1, in 100% T2, in 94% T3, and in 100% T4.
*Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, PA
†Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Reprints: Carol L. Shields, Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Suite 1440, 840 Walnut St, Philadelphia, PA 19107 (e-mail: firstname.lastname@example.org).
Supported by Eye Tumor Research Foundation, Philadelphia (C.L.S.); Mellon Charitable Giving from the Martha W. Rogers Charitable Trust (C.L.S.); and American Society of Cataract and Refractive Surgery Foundation (H.J.K.).
The authors state that they have no conflicts of interest to disclose.
Received January 19, 2012
Accepted February 24, 2012